2020
DOI: 10.1016/j.jaut.2019.102392
|View full text |Cite
|
Sign up to set email alerts
|

An overview of autoantibodies in rheumatoid arthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
153
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 239 publications
(153 citation statements)
references
References 154 publications
0
153
0
Order By: Relevance
“…RF is likely to exert its pathogenic properties via the creation of immune complexes. Then, proinflammatory cytokines, such as TNF- α and IL-1 β , are stimulated and contributing in chronic inflammation and bone destruction [ 59 ].…”
Section: Discussionmentioning
confidence: 99%
“…RF is likely to exert its pathogenic properties via the creation of immune complexes. Then, proinflammatory cytokines, such as TNF- α and IL-1 β , are stimulated and contributing in chronic inflammation and bone destruction [ 59 ].…”
Section: Discussionmentioning
confidence: 99%
“…Despite the role of these auto-antibodies being still unclear, multiple studies have shown that seropositive patients are likely to develop a more severe disease when compared to seronegative patients [ 44 , 45 ]. Serum rheumatoid factor (RF) and anti-CCP are currently used as biomarkers for the diagnosis of RA [ 6 ]. These antibodies (Abs) appear many years prior to RA onset, during the so-called “pre-clinical” course of the disease [ 46 , 47 ].…”
Section: Ra Immunopathogenesismentioning
confidence: 99%
“…RA usually affects hands, feet, and wrists, leading to progressive bone and cartilage damage, resulting in deformities, joints loss of function, and reduced independence in performing daily activities [ 4 , 5 ]. RA clinical manifestations are usually not confined to musculoskeletal system, but also involve cardiovascular system, kidneys, lungs, liver and skin [ 6 ]. RA onset is usually insidious.…”
Section: Introductionmentioning
confidence: 99%
“…ACPA (anti-citrullinated protein antibody) and RF (rheumatoid factor) are two widely accepted autoantibodies used in clinical practice as biologic markers of RA [6]. Nonetheless, neither of these two markers has sufficient specificity or sensitivity for effective diagnosis of all RA patients, and neither autoantibody allows classification of patient subpopulations or patient outcome [6]. Recently, CTHRC1 has emerged as a new biomarker that may contribute to improved RA diagnosis and assessment of disease activity [7,8].…”
Section: Introductionmentioning
confidence: 99%